WFC
77
3
GS
62
3
AVGO
61
-14
CINF
53
2
MCD
36
-2
AAPL
46
6
CFG
68
8
CAT
48
2
C
75
3
TMO
42
2
PG
58
2
JBHT
40
14
HRL
48
-2
OKE
56
3
MTB
67
4
SRE
54
2
SE
79
-4
LEN
22
-11
NI
75
5
APA
48
2
WFC
77
3
GS
62
3
AVGO
61
-14
CINF
53
2
MCD
36
-2
AAPL
46
6
CFG
68
8
CAT
48
2
C
75
3
TMO
42
2
PG
58
2
JBHT
40
14
HRL
48
-2
OKE
56
3
MTB
67
4
SRE
54
2
SE
79
-4
LEN
22
-11
NI
75
5
APA
48
2
Financhill
Back

Perspective Therapeutics 10K Form

Buy
52

CATX
Perspective Therapeutics

Last Price:
$3.3300
Seasonality Move:
8180.82%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CATX News And Ratings

See the #1 stock for the next 7 days that we like better than CATX

CATX Financial Statistics

Sales & Book Value

Annual Sales: $3.6M
Cash Flow: $-26.2M
Price / Cash Flow: 0
Annual Sales: $3.84
Price / Book: 0.87

Profitability

EPS (TTM): -1.25000
Net Income (TTM): $-85.2M
Gross Margin: $817K
Return on Equity: 0%
Return on Assets: 0%

Perspective Therapeutics Earnings Forecast

Key Perspective Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for CATX is 23.00%.
  • The Selling, General & Administrative Expenses for CATX have been equal to 200.08% of Gross Profit Margin.
  • Per Share Earnings over the last 31 years have been positive in 17 years.

Perspective Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CATX
Website: perspectivetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CATX Technical Analysis vs Fundamental Analysis

Buy
52
Perspective Therapeutics (CATX) is a Buy

Is Perspective Therapeutics a Buy or a Sell?